Thyroid Diseases: Dottorini ME

Gharib H, Papini E, Valcavi R, Baskin HJ, Crescenzi A, Dottorini ME, Duick DS, Guglielmi R, Hamilton CR, Zeiger MA, Zini M, Anonymous00012. · No affiliation provided · Endocr Pract. · Pubmed #16596732 No free full text.

Abstract: Thyroid nodules are common and are frequently benign. Current data suggest that the prevalence of palpable thyroid nodules is 3% to 7% in North America; the prevalence is as high as 50% based on ultrasonography (US) or autopsy data. The introduction of sensitive thyrotropin (thyroid-stimulating hormone or TSH) assays, the widespread application of fine-needle aspiration (FNA) biopsy, and the availability of high-resolution US have substantially improved the management of thyroid nodules. This document was prepared as a collaborative effort between the American Association of Clinical Endocrinologists (AACE) and the Associazione Medici Endocrinologi (AME). Most Task Force members are members of AACE. We have used the AACE protocol for clinical practice guidelines, with rating of available evidence, linking the guidelines to the strength of recommendations. Key observations include the following. Although most patients with thyroid nodules are asymptomatic, occasionally patients complain of dysphagia, dysphonia, pressure, pain, or symptoms of hyperthyroidism or hypothyroidism. Absence of symptoms does not rule out a malignant lesion; thus, it is important to review risk factors for malignant disease. Thyroid US should not be performed as a screening test. All patients with a palpable thyroid nodule, however, should undergo US examination. US-guided FNA (US-FNA) is recommended for nodules > or = 10 mm; US-FNA is suggested for nodules < 10 mm only if clinical information or US features are suspicious. Thyroid FNA is reliable and safe, and smears should be interpreted by an experienced pathologist. Patients with benign thyroid nodules should undergo follow-up, and malignant or suspicious nodules should be treated surgically. A radioisotope scan of the thyroid is useful if the TSH level is low or suppressed. Measurement of serum TSH is the best initial laboratory test of thyroid function and should be followed by measurement of free thyroxine if the TSH value is low and of thyroid peroxidase antibody if the TSH value is high. Percutaneous ethanol injection is useful in the treatment of cystic thyroid lesions; large,symptomatic goiters may be treated surgically or with radioiodine. Routine measurement of serum calcitonin is not recommended. Suggestions for thyroid nodule management during pregnancy are presented. We believe that these guidelines will be useful to clinical endocrinologists, endocrine surgeons, pediatricians, and internists whose practices include management of patients with thyroid disorders. These guidelines are thorough and practical, and they offer reasoned and balanced recommendations based on the best available evidence.

Mansi L, Moncayo R, Cuccurullo V, Dottorini ME, Rambaldi PF. · Nuclear Medicine Division, Second University of Naples, Naples, Italy. · Q J Nucl Med Mol Imaging. · Pubmed #15243406 links to  free full text

Abstract: Diagnostic strategy in thyroid cancer is conditioned by epidemiological, pathophysiological, cost-effective issues changing with age and countries. Nuclear medicine has a role mainly in differentiated carcinomas, i.e. in the large majority of thyroid cancers. In diagnosis of thyroid nodule (99m)Tc-perthecnetate is indicated in patients with low TSH levels, multinodular goiter, solid nodules at US negative at FNA. Radiolabeled somatostatin analogs or Metaiodobenzylguanidine (MIBG) can be used in suspicion of medullary carcinoma. There is no role in staging. WBS with 131I has a role after surgical resection of the thyroid gland and it is no more suggested before ablative therapy, because of the possible stunning effect. In the follow-up thyroglobulin (Tg) test is mandatory both after therapy withdrawal or after rhTSH administration. Some authors already suggest to use this test alone, as 1st step, in patients with differentiated carcinoma at low risk of recurrence, but this approach is not yet generally accepted and it has not yet been validated in tumors at intermediate/high risk. WBS with 131I is ever indicated when autoantibodies can affect reliability of Tg values and in presence of high Tg levels to better define a radiometabolic therapy. In case of negative WBS, PET-FDG can be proposed. In WBS, 123I can be an alternative to 131I, but it is not yet generally accepted mainly because of its higher costs. The clinical use of rhTSH to increase accuracy both of Tg and WBS can be already accepted in patients at high risk following hypothyroidism, with a worst prognosis or a low pituitary response.

Dottorini ME. · U.O. Medicina Nucleare Ospedale di Circolo Piazzale Solaro 3, 21052 Busto Arsizio, VA, Italy. · Rays. · Pubmed #11370542 No free full text.

Abstract: Differentiated thyroid carcinoma is rare in childhood and shows different characteristics as compared to thyroid carcinoma in adults. The male/female ratio is different, it has a higher aggressiveness, locoregional and distant metastases are frequent, response to surgery and 131I radioiodine therapy is optimal. A better knowledge of these characteristics has resulted in the understanding of some relevant aspects of the pathogenesis and natural history of the disease, the suitability of the therapeutic approach and the incidence of adverse side-effects. The increased incidence of differentiated thyroid carcinoma in childhood following the Chernobyl nuclear accident of April 1986 renewed the interest of the scientific community and the public opinion and allowed an in-depth study of some important aspects correlated with the carcinogenic effect of ionizing radiation.

Rubino C, de Vathaire F, Dottorini ME, Hall P, Schvartz C, Couette JE, Dondon MG, Abbas MT, Langlois C, Schlumberger M. · Unite INSERM XUR521, Gustave Roussy Institute, 39 rue Camille Desmoulins, Villejuif 94 805, France. · Br J Cancer. · Pubmed #14583762 links to  free full text

Abstract: The late health effects associated with radioiodine ((131)I) given as treatment for thyroid cancer are difficult to assess since the number of thyroid cancer patients treated at each centre is limited. The risk of second primary malignancies (SPMs) was evaluated in a European cohort of thyroid cancer patients. A common database was obtained by pooling the 2-year survivors of the three major Swedish, Italian, and French cohorts of papillary and follicular thyroid cancer patients. A time-dependent analysis using external comparison was performed. The study concerned 6841 thyroid cancer patients, diagnosed during the period 1934-1995, at a mean age of 44 years. In all, 17% were treated with external radiotherapy and 62% received (131)I. In total, 576 patients were diagnosed with a SPM. Compared to the general population of each of the three countries, an overall significantly increased risk of SPM of 27% (95% CI: 15-40) was seen in the European cohort. An increased risk of both solid tumours and leukaemias was found with increasing cumulative activity of (131)I administered, with an excess absolute risk of 14.4 solid cancers and of 0.8 leukaemias per GBq of (131)I and 10(5) person-years of follow-up. A relationship was found between (131)I administration and occurrence of bone and soft tissue, colorectal, and salivary gland cancers. These results strongly highlight the necessity to delineate the indications of (131)I treatment in thyroid cancer patients in order to restrict its use to patients in whom clinical benefits are expected.

Ravetto C, Colombo L, Dottorini ME. · Pathology Department, Ospedale di Circolo, Busto Arsizio, Italy. · Cancer. · Pubmed #11156519 links to  free full text

Abstract: BACKGROUND: Nodular thyroid disease is a frequent occurrence in clinical practice. The numerous diagnostic procedures available make the diagnosis of thyroid carcinoma possible but, if not used rationally, may lead to an unjustified increase in cost with little practical gain. The aim of the current study was to evaluate the usefulness of fine-needle aspiration (FNA) of palpable thyroid nodules after functional evaluation by thyroid scintigraphy. METHODS: The authors retrospectively evaluated 37,895 FNAs performed between 1980-1997. FNAs were performed on palpable thyroid nodules, except unambiguously autonomous ("hot") nodules, at the time of thyroid scintigraphy. Cytologic and histologic diagnoses were compared in 4069 patients to estimate the accuracy of FNA. RESULTS: The sensitivity of FNA was 91.8% and the specificity was 75.5%. A pretest probability of thyroid carcinoma of 4% was reduced to 0.4% in the patients with a cytologic diagnosis of benign nodular goiter, whereas it was increased to 90.7% in those patients with a positive cytologic diagnosis. Only in the case of a cytologic diagnosis of "follicular neoplasm" was the probability of malignancy not changed significantly and histologic evaluation of the nodule was necessary. CONCLUSIONS: In the majority of cases, FNA of palpable thyroid nodules allows for the identification of thyroid carcinoma and the planning of subsequent appropriate therapy. This can be achieved by using simple and inexpensive procedures, if cooperation among clinicians, pathologists, and nuclear physicians is maximized.

Guglielmi R, Pacella CM, Dottorini ME, Bizzarri GC, Todino V, Crescenzi A, Rinaldi R, Panunzi C, Rossi Z, Colombo L, Papini E. · Department of Endocrine, Metabolic and Digestive Diseases, Ospedale Regina Apostolorum, Albano, Rome, Italy. · Thyroid. · Pubmed #10090318 No free full text.

Abstract: Liver metastases from differentiated thyroid tumors are unusual clinical findings, and are only rarely hyperfunctioning. We report a case of thyrotoxicosis caused by a huge and surgically unresectable liver metastasis from follicular thyroid cancer, unresponsive to treatment with large doses of thionamides. To avoid the hazardous side effects of (131)I treatment in a severely thyrotoxic patient, a preliminary debulking of the liver mass was performed by means of percutaneous interstitial laser photocoagulation. Three treatments (total energy delivery: 7200 J) were performed under ultrasound guidance, with no serious complications, during a 2-week period. One month later, serum thyroid hormones had decreased, general condition was improved, and magnetic resonance evaluation revealed large and well-defined areas of necrosis of metastatic tissue. During the following 10 months, the patient underwent 3 radioiodine treatments. Eighteen months after diagnosis, thyroid hormones were within normal levels, liver mass decreased, and the clinical condition markedly improved. The combination of percutaneous interstitial laser photocoagulation treatment and radioiodine therapy made possible the effective management of a hyperfunctioning and surgically untreatable liver metastasis from thyroid follicular carcinoma, avoiding the side effects of (131)I therapy in a thyrotoxic patient and increasing the effectiveness of radioiodine-induced neoplastic tissue ablation.